Neoplasms

Symptoms and General Pathology

All Conditions

Musculoskeletal Diseases

Blood and Lymph Conditions

Neoplasm Metastasis

Bone Neoplasms

Bone Marrow Diseases

Neoplastic Processes

Bone Diseases

Hematologic Diseases

Micronutrients

All Drugs and Chemicals

Bone Density Conservation Agents

Vitamins

Vitamin D

Cholecalciferol

Calcium

Calcium, Dietary

Trace Elements

Hormones

Vitamin D3

Calciferol

Eligible patients will receive JMT103 120 mg SC Q4W for up to 13 cycles.

Eligible patients will receive JMT103 120 mg SC Q8W for up to 7 cycles.

Eligible patients will receive JMT103 180 mg SC Q8W for up to 7 cycles.

JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 4-week cycle.

Drug: JMT103- 120 mg SC Q4W

JMT103 is administered subcutaneously at a dose of 120 mg on day 1 of each 8-week cycle.

Drug: JMT103- 120 mg SC Q8W

JMT103 is administered subcutaneously at a dose of 180 mg on day 1 of each 8-week cycle.

Drug: JMT103- 180 mg SC Q8W

Calcium is given orally at a dose of 500 mg at least, once daily. Vitamin D is given orally at a dose of 400 IU at least, once daily.

Dietary Supplement: Calcium Dietary Supplement: Vitamin D

Jin Li, MD

This is a randomized, open-label, dose-finding, multi-centre, phase Ⅰb study to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.

The objective of this trial is to evaluate the efficacy and safety of JMT103 in patients with bone metastases from solid tumors.

Eligible patients will be randomly assigned to receive JMT103 120mg subcutaneously (SC) every 4 weeks (Q4W), 120mg subcutaneously (SC) every 8 weeks (Q8W) and 180mg subcutaneously (SC) every 8 weeks (Q8W) in a 1:1:1 ratio. Patients will receive the treatment until the completion of 48 weeks of treatment, intolerable toxicity, loss to follow-up, withdrawal (patient's decision or investigator's decision), whichever comes first.

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

A Randomized, Open-Label, Dose-finding, Multi-centre, Phase Ib Study toEvaluate the Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

SRE is defined as pathological fracture, radiotherapy to bone, surgery to bone, or spinal cord compression.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors	NCT04630522	Bone Metastases...	Drug: JMT103- 1... Drug: JMT103- 1... Drug: JMT103- 1... Dietary Supplem...	18 Years -	Shanghai JMT-Bio Inc.
Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors	NCT04630522	Bone Metastases...	Drug: JMT103- 1... Drug: JMT103- 1... Drug: JMT103- 1... Dietary Supplem...	18 Years -	Shanghai JMT-Bio Inc.

Spots Global Cancer Trial Database for dietary supplement: calcium dietary supplement: vitamin d